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Abstract   
Introduction: Mineral trioxide aggregate (MTA) is an endodontic material with different 
clinical applications e.g. root-end filling, pulp capping and perforation repair.  It has been 
reported to possess antimicrobial and antifungal activities. The aim of this study was to examine 
the effect of White MTA on formalin-induced hyperalgesia in a rat with inflammatory pain. 
Materials and Methods: Inflammatory pain was induced by subcutaneous (SC) injection 
of formalin (40 µL, 2.5%) into the rat upper lip. The nociceptive behavioral responses i.e. 
shaking of the lower jaw and face rubbing were quantified. 40 µL of eugenol (50 mg/kg), 
WMTA (20 mg/0.2 mL) or ketoprofen were injected solely or in combination with formalin 
2.5% and the behavioral responses were compared with those observed after formalin treatment 
alone. One-way ANOVA, Tukey were used for analysis of data.  
Results: Formalin 2.5% provoked a biphasic nociceptive response, with an early and short 
lasting first tonic phase followed by a second phase. Solely SC injection of either WMTA or 
ketoprofen (a non steroidal anti-inflammatory drug) did not stimulate any significant 
nociceptive behaviour. However, injection of eugenol (a pain relieving agent) induced the early 
phase not the tonic phase of nociceptive response. WMTA, eugenol or ketoprofen injection 20 
min before formalin injection attenuated the first phase but somehow prevented the induction of 
the second phase of nociceptive responses which were produced by formalin. Behavioural 
nociceptive responses including shaking of the lower jaw and face rubbing were significantly 
reduced when the subject was pretreated with either WMTA or ketoprofen (P<0.001). 
Conclusion: In this study, WMTA induced pain reduction by suppression of the formalin-
induced nociceptive response. [Iranian Endodontic Journal 2009;4(3):81-6 
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Introduction 
Orofacial pain may be a result of endodontic 
pathology (1,2). Tissue acidification occurring 
after dental pulp inflammation with/without 
periapical lesions may result into orofacial pain 
(3). It can also significantly contribute to 
postoperative pain  (4). Dental materials in 
direct contact with the oral tissues may also 
cause inflammatory reactions. Mineral trioxide 
aggregate (MTA) is a dental material 
commonly used for root-end fillings, pulp 
capping and perforation repairs (5-11). MTA 
possess adequate physical (12,13), chemical 
(14,15)  and  biological  (16)  properties.  It has  
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Figure 1. A) Observation box: After injection of 
each drug, the rat was placed in a plexiglass 
observation box. B) Injection site: Each drug was 
injected into the upper lip ipsilaterally, just 
lateral to the nose. Formalin induced 
inflammation at the injection site. 
 
been also reported to be a non-cytotoxic 
(15,17-19) and non-genotoxic (20,22,23) dental 
material. The antibacterial (23,24) and 
antifungal (25-27) activities of MTA have also 
been documented. In orofacial formalin tests on 
animal models, nociception was mediated by 
craniofacial sensory afferent neurons; 
assessments of the magnitude of nociceptive 
sensations were elicited by long-lasting supra-
threshold chemical stimulus (28,29). 
Trigeminal nerve innervates the orofacial 
regions.  It also carries the pain impulses of this 
region i.e. teeth and surrounding structures 
(30). Subcutaneous (SC) injection of dilute 
formalin has been shown to activate 
unmyelinated polymodal nociceptors (31) and 
produce inflammatory pain. Tissue 
inflammation results in release of inflammatory 
mediators such as prostaglandins causing 
hyperalgesia (32). Ketoprofen (KP) is a 
nonsteroidal anti-inflammatory drug (NSAID); 
it has inhibitory effect on inflammatory 
mediators (33) and provides effective analgesia 
in the presence of tissue inflammation. 
Eugenol, a phenolic dental medicament, has 
been widely used as a topical sedative of pain 
and inflammation for pulpitis and dentine 
hyperalgesia (34). In the present study, the 
suppressive effect of WMTA against formalin-
induced inflammatory pain in the orofacial 
region of rats was investigated and compared 
with the analgesic effects of ketoprofen and 
eugenol. 
 
Materials and Methods 
This study was approved by Ethical committee 
of Shahid Beheshti Medical University. 
Experiments were performed on  male 
Sprague-Dawley rats (n=69, 180–200 g) 
housed at 23 ± 1˚C and 12-h light/dark cycles, 
acclimatized to the laboratory conditions for at 
least 72 h before use, with free access to food 
and water. Tests were carried out during the 
light phase (between 10:00 am and 5:00 pm) in 
a silent room. Animals were tested once and 
were then sacrificed at the end of experiments.  
All solutions were administered by SC 
injection (40 µL). Drug doses were chosen 
based on pilot or preliminary experiments using 
values from the literature and our previous 
work (35). The 2.5% formalin was prepared by 
diluting the stock aqueous 37% formaldehyde 
solution (Sigma, UK) in 0.9% isotonic saline. 
MTA was prepared according to the 
manufacturer’s instruction.  
Animals were assigned to five treatment 
groups: (1) formalin 2.5% (n=10); (2) 
injections of eugenol alone (50 mg/kg, n=10) or 
eugenol followed by formalin 2.5% (n=10) 20 
min later; (3) WMTA (20 mg dissolved in 0.2 
mL saline, n=10) alone or injection of WMTA 
(n=10) 20 min prior to formalin treatment; (4) 
ketoprofen (30 mg/kg, n=3) alone or ketoprofen 
followed by formalin (n=10) 20 min later and 
(5) saline 40µL (n=3), as a vehicle or no 
treatment (needle insertion only n=3).  
The orofacial formalin test was performed 
according to Clavelou et al. (29) and Raboisson 
and Dallel (30). That is, before the injection, 
each rat was placed in a transparent plexiglass 
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mirror placed at an angle of 45˚) for 30 min, in 
order to minimize stress-related behaviours 
(Figure 1A). They received a SC 40 μL 
injection of test materials into the upper lip, just 
lateral to the nose (Figure 1B), using a 30-
gauge sterile needle. The rats were immediately 
returned to the transparent box for a 45-min 
observation. Rubbing of the injected area was 
regarded as the parameter of nociceptive 
response. Duration of nociceptive response was 
cumulatively recorded using a stopwatch, in 
consecutive 5-min intervals over a 45-min 
period, and was considered as an index of 
nociception. The nociceptive response was 
clearly biphasic with the first-neurogenic-phase 
peak occurring at approximately 5 mins after 
formalin injection and subsiding transiently 
over the next 5 mins. The second-
inflammatory-phase peaked between 20-25 
min. Responses that occurred during the first 5-
10 min period following formalin injection 
were recorded as the first phase of nociception, 
and those occurring between 20 and 35 min as 
the second phase. Response scoring was 
performed according to Clavelou et al. (29). 
This score was based on four scales including 0 
for normal behaviour e.g. grooming; 1, 
abnormal head movements; 2, abnormal 
continuous shaking of the lower jaw; 3, 
excessive rubbing of the mouth. Nociceptive 
scores were calculated with 5-min intervals at 
the end of observation, according to the 
following formula (T=time): Nociceptive score 
= [(1×T in scale 1) + (2×T in scale 2) + (3×T in 
scale 3)]/ 300 s (31,36).  
The nociceptive behavioural responses were 
averaged into 5-min intervals to decrease 
minute by minute variability.  
The results were expressed as mean ± S.E.M. 
Parametric tests [two tailed student t-test and 
ANOVA (analysis of variance with post hoc 
comparisons via Tukey’s HSD test)] and 
appropriate statistical software (Version 6, 
StatSoft, Tulsa, USA) were used. P<0.05 was 
considered significant.  
 
Results  
SC injection of 40 µL of formalin 2.5% elicited 
a typical biphasic nociceptive time course with 
early or short lasting phase (5-10 min) followed 
by a second prolonged tonic phase  (20-30 min) 
 
Figure 2. Effect of different treatments on 
nociceptive scores recorded in different conditions.  
 
that subsided after 45 minutes (Figure 2). Rats 
showed shaking of the lower jaw (Figures 3A 
and B) and then sustained face rubbing 
episodes (Figures 3C and D). Adminstration of 
WMTA, Eugenol and Ketoprofen before the 
formalin injections all statistically reduced 
pain.  
Injection with WMTA alone did not cause 
nociceptive response (Figures 2 and 3). Also 
the injection of WMTA 20 min prior to 
formalin resulted in a decrease in nociceptive 
score (Figure 2) and significant reduction in 
lower jaw shaking and face rubbing in both 
behavior phases (P<0.001) (Figure 3). Eugenol 
injections either alone or 20 min before 
formalin treatment induced less persistent 
behavioral score. Injection of eugenol alone did 
not completely eliminate the first phase of pain 
behaviour but caused a significant decrease in 
the related face rubbing compared to formalin 
injection alone, while almost completely 
abolished the face rubbing in the second phase 
of nociceptive behaviour (Figures 3A and B). 
Ketoprofen, a NSAID, when administered 20 
min before formalin injection elicited a strong 
inhibitory effect on the hyperalgesic reaction 
caused by formalin during the both phases of 
pain responses (Figures 2 and 3). Interestingly, 
no significant difference was observed between 
the suppressive effects of ketoprofen and 
WMTA (with or without formalin) both on the 
lower jaw shaking and face rubbing. Here, 
saline did not induced statistically significant 
nociceptive responses per se. 
 
Discussion 
The orofacial region is one of the most densely 
innervated areas of the body; this region is 
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Figure 3. Effect of different treatments on the first (A) and the second (B) phases of shaking of the lower 
jaw and (C) the first phase (5-10 min post injection) and (D) the second phase (20-35 min post injection) 
of face rubbing nociceptive responses. Asterisks represent a significant difference as compared to 
formalin response.  
 
Formalin SC injection into the bilateral upper 
lip causes a biphasic nociceptive response 
which is useful for clinical pain studies (28). 
The primary phases after formalin application 
has been attributed to a direct activation of C-
fiber nociceptors; while the second and more 
persisted inflammatory phase is generally 
believed to be due to the local release of 
inflammatory mediators (37,39).  
Information about physiological and biological 
aspects of root-end filling materials such as 
MTA is important for their clinical use. MTA 
has become a popular material to seal 
communication between the root canal system 
and external environment (40,41). It has also 
been recommended for root perforations, root 
end filling and apexification (42,43). MTA is 
commercially available in two different 
versions: grey-colored (GMTA) and white-
colored. Both have been reported to consist of 
fine hydrophilic particles, but with slightly 
different composition (15). Both gray MTA and 
white MTA have been reported to produce 
effective antifungal (25-27) and antimicrobial 
(24) activities, which could be attributed to 
calcium hydroxide release or presumably be 
due to its high pH. These two factors have been 
reported to be responsible for the 
biocompatibility of MTA (8,44). It has been 
shown that Ca2+ release from MTA could be 
the main factor that contributed to pulp repair 
(45).  
In the present study the exact mechanism 
responsible for the anti-inflammatory pain 
reduction of MTA has not been determined; but 
we can speculate that the high pH induced by 
MTA may be contributory. It has been shown 
that protons can evoke pain through acid-
sensing ion channel (ASICs) activation (46), 
which is present in primary sensory neurons of 
the trigeminal nerve (47). Therefore, high pH 
produced by MTA may eliminate the low pH 
induced by inflammatory mediators. 
It is suggested that tissue injury caused by 
direct formalin injection in the orofacial area 
might be as a result of the production of 
prostaglandin, which in turn induces 
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steroidal anti-inflammatory drug which 
effectively kills inflammatory pain in different 
animal models as well as humans (46,47). Our 
findings showed that the anti-inflammatory 
pain activity of white ProRoot MTA is almost 
comparable to ketoprofen, as an anti-
inflammatory pain reducing agent. Injection of 
a pain relieving agent (eugenol) produced the 
early short-lasting pain behaviour, but not the 
second tonic response.  
 
Conclusion  
This study suggests that white MTA does not 
appear to have any irritant effect on the nerve 
tissue and its anti-inflammatory pain reduction 
is comparable to ketoprofen, more effective 
than eugenol. MTA behaved as a palliative 
agent in this experimental animal model, 
further research is required to confirm the anti-
inflammatory and analgesic properties of MTA.  
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